Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide doxorubicin vincristine and prednisone in diffuse large B-cell lymphoma

机译：缺氧诱导因子-1a的表达预测利妥昔单抗加环磷酰胺阿霉素长春新碱和泼尼松在弥漫性大B细胞淋巴瘤中的获益

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 International Journal of Clinical and Experimental Pathology
作者
Jie Jin; Lihong Cao; Lijun Wang; Zhaoming Wang; Wei Ding; Liping Mao; Shanshan Suo; Zhengping Zhuang; Hongyan Tong;
展开▼
作者单位

展开▼
年(卷),期 2018(11),9
年度 2018
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;病理学;
关键词
Diffuse large B-cell lymphoma; immunohistochemistry; hypoxia-inducible factor; prognosis;

机译：弥漫性大B细胞淋巴瘤;免疫组化;缺氧诱导因子;预后;

相似文献

外文文献
中文文献
专利

1. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: Results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi [J] . MerliF., LuminariS., RossiG., Leukemia and lymphoma . 2012,第4期

机译：环磷酰胺，阿霉素，长春新碱，泼尼松和利妥昔单抗与表柔比星，环磷酰胺，长春花碱，泼尼松和利妥昔单抗用于老年“适合”弥漫性大B细胞淋巴瘤患者的初始治疗：Intergruppo Italiano Linfomi的ANZINTER3试验结果
2. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma [J] . Porrata Luis F., Ristow Kay M., Habermann Thomas M., Leukemia and lymphoma . 2014,第12期

机译：利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松治疗周期中的外周血绝对淋巴细胞/单核细胞比率预测弥漫性大B细胞淋巴瘤的临床结局
3. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone [J] . NamS.J., GoH., PaikJ.H., Leukemia and lymphoma . 2014,第11期

机译：M2巨噬细胞增多预示着利妥昔单抗，环磷酰胺，阿霉素，长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者预后不良
4. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma [C] . Bohua Li, Hao Wang, Yajun Guo, International conference of molecular simulations and applied informatics technologies . 2012

机译：具有抗利妥昔单抗的B细胞淋巴瘤的有效抗肿瘤活性的利妥昔单抗变体的表征
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Genetic polymorphism at BCL2 as a predictor for rituximab cyclophosphamide doxorubicin vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma [O] . Morteza Bashash, Joseph M. Connors, Randy D. Gascoyne, 2017

机译：BCL2基因多态性可预测弥散性大B细胞淋巴瘤患者的利妥昔单抗环磷酰胺阿霉素长春新碱和泼尼松的疗效
7. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [O] . Nathalie A. Johnson, Graham W. Slack, Kerry J. Savage, 2012

机译：用Rituximab加环磷酰胺，多柔比蛋白，长春酮和泼尼松治疗弥漫性大B细胞淋巴瘤MYC和BCL2的同时表达

Expression of hypoxia-inducible factor-1a predicts benefit from rituximab plus cyclophosphamide doxorubicin vincristine and prednisone in diffuse large B-cell lymphoma

著录项

相似文献

相关主题

期刊订阅